Psychiatry

The guidelines contain safety warnings because psychedelic drugs could produce psychoactive effects such as mood, cognitive changes, and hallucinations.

The results show 55.4% of patients in the ketamine group had a response, compared to 41.2% of patients in the ECT group.

Patients with high attendance rates within the lifestyle intervention group lost more weight than those with medium and low rates.

Patients with anxiety or depression who engaged in health-related social media usage were significantly more likely to report to report intentions to quit smoking, endorse past 12-month attempts at smoking cessation, and were more likely to meet national recommendation for weekly strength training.

The results show high centrality of anxiety and depression in patients with COVID-19 and anxiety had the highest bridge influence in the network.

After making adjustments, the results show a positive association between alcohol dependence at 18 years and depression at age 24 years. However, there was no association between the rate of change and depression.

The new guidelines call for MDD screening for adults, including pregnant and postpartum individuals and those aged 65 years and older, which would have a moderate net benefit.

New CDC survey data show an estimated 47 million adults in the US have ever been diagnosed with depression, with clear disparities based on demographics and regions.

Young adults with psychiatric and behavioral disorders are more likely to experience a decline in sleep intensity and sleep depth more dramatically after adolescence.

The results of the study presented during SLEEP 2023 show the rate of suicidality was 46% in individuals who reported moderate-to-severe nightmares.

A preference for eveningness was significantly associated with worse overall sleep difficulties, longer sleep latency, reduced sleep satisfaction, more prolonged sleep inertia, more daytime naps, and more severe depressive symptomatology.

The results show engagement in the Telehealth Collaborative Care program visits was greater compared to the Telehealth Enhanced Referral group.

Participants who only initiated non-stimulant therapy for ADHD had significantly greater odds of past-year prescription stimulant misuse than the population controls.

Patients with comorbid major depressive disorder were more likely to have a diagnoses of tobacco, alcohol, opioid, cannabis, stimulants, hallucinogens, sedatives-hypnotics, or anxiolytic use disorders compared to patients with only systemic lupus erythematous.

The rate of sleep apnea is greater in patients with bipolar disorder and depression.

The results show 26.3% of patients in the daily cannabis use only group endorsed 2 or more items on the symptom checklist, consistent with DSM-5 SUD, compared to 30.2% of the other drug use group and 51.8% of the daily cannabis and other drug use group.

A prospective cohort analysis of Denmark residents suggests correlation between cannabis overuse and risk of psychiatric conditions.

New prospective data show more adult patients achieved clinical response with ketamine than the historic standard ECT over a 6-month regimen.

Buprenorphine is available either in a weekly injection formulation and a monthly formulation for patients already being treated with buprenorphine.

The study revealed that healthcare workers with psychiatric disorders had slightly lower Anti-SARS-CoV-2-Spike IgG levels before their third COVID-19 vaccination, but this effect was mediated by age and body mass index.

The LYNX drug development platform is able to deliver drug consistently, while minimizing peaks and troughs of drug levels compared to daily medicine.

Depression is linked with an increased incidence of multiple nonoverlapping physical conditions requiring hospital treatment, including endocrine, musculoskeletal, and vascular diseases.

Clozapine treatment may offer the added benefit of improved sleep in patients with schizophrenia, according to a meta-analysis.

According to the study, gay and bisexual adolescents show higher rates of sleep issues and sleep disturbances.

The extended-release injectable suspension treatment represents the first subcutaneous, long-acting formulation of risperidone.

The long-acting injectable can be administered once every 2 months to either treat schizophrenia or serve as a maintenance monotherapy for bipolar disorder.

An analysis of data from more than 119,000 pregnancies suggests women with prenatal depression were at increased risk for multiple forms of cardiovascular disease within the first 2 years following delivery relative to their counterparts without prenatal depression.

Treatment with benzodiazepines, antipsychotics, and antidepressants was associated with an increased risk of all-cause hospitalization or mortality, while mood stabilizer treatment did not have a statistically significant association with any of the predetermined outcomes and ADHD medications were linked to a lower risk of psychiatric hospitalization.

New research highlights the shared and unique characteristics of sleep and rest-activity rhythm measures among patients with schizophrenia.